Cytokinetics Announces Initiation of Phase 1 Clinical Study of AMG 594, a Cardiac Troponin Activator
Go back to Cytokinetics Announces Initiation of Phase 1 Clinical Study of AMG 594, a Cardiac Troponin Activator| CYTOKINETICS (NASDAQ: CYTK) | Delayed: 73.89 -1.46 (1.94%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $75.35 | 52 Week High | $13.18 | |||
| Open | $74.31 | 52 Week Low | $6.00 | |||
| Day High | $74.89 | P/E | N/A | |||
| Day Low | $73.69 | EPS | $-1.24 | |||
| Volume | 269,060 | |||||
